158 related articles for article (PubMed ID: 8549285)
1. The role of new quinolones in the treatment of respiratory tract infections.
Finch RG
Drugs; 1995; 49 Suppl 2():144-51. PubMed ID: 8549285
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.
Baquero F; Cantón R
J Antimicrob Chemother; 1996 May; 37 Suppl A():1-18. PubMed ID: 8737121
[TBL] [Abstract][Full Text] [Related]
3. The role of fluoroquinolones in respiratory tract infections: community acquired pneumonia.
García-Rodríguez JA; Muñoz Bellido JL
Int J Antimicrob Agents; 2000 Nov; 16(3):281-5. PubMed ID: 11091048
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
5. Emerging resistance problems among respiratory tract pathogens.
Lister PD
Am J Manag Care; 2000 May; 6(8 Suppl):S409-18. PubMed ID: 10977480
[TBL] [Abstract][Full Text] [Related]
6. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
Momméja-Marin H; Carbon C
Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolones in respiratory infections.
Klein NC
Semin Respir Infect; 1991 Sep; 6(3):131-5. PubMed ID: 1754733
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
Esposito S; Noviello S; Ianniello F
Chemotherapy; 2000; 46(5):309-14. PubMed ID: 10965095
[TBL] [Abstract][Full Text] [Related]
9. The place of quinolones in the treatment of respiratory tract infections.
van der Meer JW
Pharm Weekbl Sci; 1989 Aug; 11(4):132-3. PubMed ID: 2677985
[TBL] [Abstract][Full Text] [Related]
10. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
11. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.
Goa KL; Bryson HM; Markham A
Drugs; 1997 Apr; 53(4):700-25. PubMed ID: 9098667
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections.
Miyazaki S; Domon H; Tateda K; Ohno A; Ishii Y; Matsumoto T; Furuya N; Yamaguchi K
Antimicrob Agents Chemother; 1997 Nov; 41(11):2582-5. PubMed ID: 9371375
[TBL] [Abstract][Full Text] [Related]
13. New developments in antibacterial choice for lower respiratory tract infections in elderly patients.
Ferrara AM; Fietta AM
Drugs Aging; 2004; 21(3):167-86. PubMed ID: 14979735
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
15. Quinolones in the treatment of lower respiratory tract infections in adult patients.
Carbon C
Drugs; 1993; 45 Suppl 3():91-7. PubMed ID: 7689458
[TBL] [Abstract][Full Text] [Related]
16. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections.
Niki Y; Tamada S; Nakabayashi M; Soejima R
Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385
[No Abstract] [Full Text] [Related]
17. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Martin SJ; Jung R; Garvin CG
Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
[TBL] [Abstract][Full Text] [Related]
18. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
Jones RN; Pfaller MA
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
[TBL] [Abstract][Full Text] [Related]
20. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
